摘要
目的探讨131I治疗甲亢患者后发生甲状腺功能减退症与TSAb、MCA的关系。方法检测和分析了150例131I治疗前、后1年和3年甲亢患者的血FT3、FT4、TSH、TSAb、MCA和131I治疗的临床资料。结果甲亢患者131I治疗前TSAb阳性率经131I治疗后率随病情好转呈逐年下降趋势,而甲减的发生在131I治疗后逐年增加并与抗体的类型有关。结论桥本甲状腺炎和Graves病伴桥本甲状腺炎合并甲亢患者避免或不宜使用131I治疗甲亢,Graves病患者为131I治疗甲亢较适宜对象,为避免过早发生甲减,检测TSAb及MCA对甲亢的诊断、鉴别诊断、确定合理的治疗方案减少甲减的发生具有重要意义。
Objective To study the value of TSAb detection for hypothyroidism after in ^131I therapy on hyperthyreosis. Methods The levels of FT3, FT4, TSH, TSAb, MCA of 129 cases with hyperthroidsm were analyzed and deter- mined before ^131I therapy and after ^131I therapy at 1 and 3 year respectively. Results The positive rate of TSAb showed a descending tendency from year to year after ^13lI therapy. The positive rate of hypothyroidism showed an ascending tendency after ^131 I therapy, which was related with the TGA, MCA, TSAb. Conclusions Detection of TSAb, MCA may has important significance in clinical diagnosis, contrasted diagnosis and right treatment of podients with hyperthroidism and could reduce the occurance of hypothroidism.
出处
《医学信息（手术学分册）》
2008年第3期211-212,共2页
Medical Information Operations Sciences Fascicule
